Walleye Capital LLC Takes Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Walleye Capital LLC purchased a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) during the 3rd quarter, Holdings Channel.com reports. The firm purchased 99,416 shares of the company’s stock, valued at approximately $2,539,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Quest Partners LLC increased its stake in Enliven Therapeutics by 87.3% during the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after purchasing an additional 742 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Enliven Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after acquiring an additional 3,559 shares in the last quarter. SG Americas Securities LLC purchased a new position in Enliven Therapeutics in the 3rd quarter worth approximately $256,000. The Manufacturers Life Insurance Company bought a new position in Enliven Therapeutics in the 2nd quarter valued at approximately $322,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Enliven Therapeutics by 25.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company’s stock valued at $441,000 after purchasing an additional 3,518 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

ELVN has been the subject of several recent analyst reports. Robert W. Baird boosted their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $37.00 target price on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Enliven Therapeutics Price Performance

Shares of ELVN opened at $23.61 on Wednesday. The firm has a market capitalization of $1.15 billion, a P/E ratio of -12.43 and a beta of 1.02. Enliven Therapeutics, Inc. has a one year low of $9.80 and a one year high of $30.03. The business has a fifty day moving average of $26.79 and a 200 day moving average of $24.14.

Insider Buying and Selling at Enliven Therapeutics

In other news, Director Richard A. Heyman sold 2,825 shares of Enliven Therapeutics stock in a transaction on Friday, October 4th. The shares were sold at an average price of $27.51, for a total transaction of $77,715.75. Following the transaction, the director now owns 125,760 shares in the company, valued at $3,459,657.60. This trade represents a 2.20 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Samuel Kintz sold 12,206 shares of the business’s stock in a transaction on Friday, October 4th. The shares were sold at an average price of $27.51, for a total transaction of $335,787.06. Following the sale, the chief executive officer now directly owns 1,036,523 shares of the company’s stock, valued at approximately $28,514,747.73. The trade was a 1.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 129,195 shares of company stock worth $3,581,772 in the last three months. 29.20% of the stock is currently owned by company insiders.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.